Search Result

Results for "

Janus+kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) EGFR (2) GSK-3 (1) IGF-1R (1) Isotope-Labeled Compounds (1) JAK (21) Microtubule/Tubulin (1) PI3K (1) Protease Activated Receptor (PAR) (1) Reference Standards (1) STAT (2)
By Research Areas:	Cancer (8) Cardiovascular Disease (1) Endocrinology (1) Infection (2) Inflammation/Immunology (14)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19569

Upadacitinib Maximum Cited Publications 26 Publications Verification ABT-494	JAK	Inflammation/Immunology
Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research .

HY-112708

Brepocitinib 3 Publications Verification PF-06700841	JAK	Inflammation/Immunology
Brepocitinib (PF-06700841) is a potent dual Janus kinase 1 (JAK1) and TYK2 inhibitor with IC₅₀s of 17 nM and 23 nM, respectively. Brepocitinib also inhibits JAK2 and JAK3 with IC₅₀s of 77 nM and 6.49 μM, respectively .

HY-19569R

Upadacitinib (Standard) 1 Publications Verification ABT-494 (Standard)	Reference Standards JAK	Inflammation/Immunology
Upadacitinib (Standard) is the analytical standard of Upadacitinib. This product is intended for research and analytical applications. Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research .

HY-112708A

Brepocitinib P-Tosylate 3 Publications Verification PF-06700841 P-Tosylate	JAK	Inflammation/Immunology
Brepocitinib (PF-06700841) P-Tosylate is a potent dual Janus kinase 1 (JAK1) and TYK2 inhibitor with IC₅₀s of 17 nM and 23 nM, respectively. Brepocitinib P-Tosylate also inhibits JAK2 and JAK3 with IC₅₀s of 77 nM and 6.49 μM, respectively .

HY-N2521

Tetramethylcurcumin FLLL31	STAT Apoptosis	Inflammation/Immunology Cancer
Tetramethylcurcumin (FLLL31), derived from curcumin, specifically suppresses the phosphorylation of STAT3 by binding selectively to Janus kinase 2 and the STAT3 Src homology-2 domain. Tetramethylcurcumin exhibits anti-inflammatory and anti-cancer effects .

HY-148785

Nimucitinib	JAK	Others
Nimucitinib is a Janus kinase (JAK) inhibitor .

HY-W727879

Upadacitinib-15N,d2 1 Publications Verification ABT-494-¹⁵N,d₂	Isotope-Labeled Compounds	Others
Upadacitinib- ¹⁵N,d₂ (ABT-494- ¹⁵N,d₂) is the deuterium-labeled Upadacitinib (HY-19569). Upadacitinib- ¹⁵N,d₂ (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib- ¹⁵N,d₂ (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib- ¹⁵N,d₂ (ABT-494) can be used for several autoimmune disorders research .

HY-148791

Pumecitinib PG-011	JAK	Inflammation/Immunology Cancer
Pumecitinib is a *Janus kinase* (JAK) inhibitor. Pumecitinib shows anti-inflammatory activity .

HY-156621

Lepzacitinib	JAK	Inflammation/Immunology
Lepzacitinib is a Janus kinase inhibitor targeting to JAK 1/3. Lepzacitinib exhibits anti-inflammatory effect and inhibits atopic dermatitis and other skin diseases .

HY-159827

Cenacitinib	JAK	Inflammation/Immunology
Cenacitinib is a potent *Janus kinase* inhibitor. Cenacitinib shows anti-inflammatory activity .

HY-19569A

Upadacitinib tartrate tetrahydrate ABT-494 tartrate tetrahydrate	JAK	Inflammation/Immunology
Upadacitinib (ABT-494) tartrate tetrahydrate is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib tartrate tetrahydrate displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib tartrate tetrahydrate can be used for several autoimmune disorders research .

HY-119935

JAK3 covalent inhibitor-1	JAK	Inflammation/Immunology
JAK3 covalent inhibitor-1 is a potent and selective janus kinase 3 (JAK3) covalent inhibitor with an IC₅₀ of 11 nM and shows 246-fold selectivity vs other JAKs .

HY-132849

Nezulcitinib TD-0903	JAK	Infection Inflammation/Immunology
Nezulcitinib (TD-0903) is an inhaled and lung-selective pan-Janus kinase (JAK) inhibitor. Nezulcitinib can be used for the research of COVID-19 associated acute lung injury and impaired oxygenation .

HY-156423

Tubulin/JAK2-IN-1	Microtubule/Tubulin JAK	Cancer
Tubulin/JAK2-IN-1 (compound 7g) is a dual inhibitor of Janus kinase 2 (JAK2) and microtubule. Tubulin/JAK2-IN-1 has potent antiproliferative activity against the cancer cells .

HY-177131

Soficitinib	JAK	Inflammation/Immunology
Soficitinib (Compound 20) is a selective tyrosine kinase 2 (TYK2) and Janus kinase 2 (JAK2) inhibitor, with IC₅₀ values of 0.5 nM and 1.2 nM, respectively. Soficitinib shows promise for research into autoimmune diseases (such as psoriasis, rheumatoid arthritis) and inflammatory diseases .

HY-W740378

1,2,3,4-Tetrahydro Staurosporin AFN-941	EGFR JAK	Others
1,2,3,4-Tetrahydrostaurosporine is a derivative of Staurosporine (HY-15141) and an inhibitor of mutant EGFR (IC₅₀=74 nM for EGFRT790M). It is selective for EGFRT790M over wild-type EGFR (IC₅₀=390 nM). It also binds to Janus kinase 3 (JAK3).

HY-161618

MJ04	JAK EGFR PI3K IGF-1R GSK-3	Inflammation/Immunology Endocrinology
MJ04 is a selective inhibitor for Janus Kinase 3 (JAK 3) with an IC₅₀ of 2.03 nM. MJ04 inhibits T cell differentation and inhibits the proinfammatory cytokines in Lipopolysaccharides (HY-D1056)‑induced macrophages. MJ04 exhibits good pharmacokinetic characters in mice, promotes hair growth in DHT-induced androgenetic alopecia (AGA) in athymic mice model, without significant toxicity (LD₅₀ >2 g/kg) .

HY-169184

GDC-9918	JAK	Cancer
GDC-9918 (compund GDC-9918) is a *Janus* kinase inhibitor .

HY-161259

JAK-IN-36	JAK	Inflammation/Immunology
JAK-IN-36 (Compound 12e) is a potent and selective inhibitor of Janus Kinase 1 (JAK1) with a IC₅₀ value of 2.2 nM. JAK-IN-36 can be used in the study of autoimmune diseases .

HY-151258

TK4g	JAK	Cancer
TK4g is a *Janus kinase* (JAK) inhibitor with the IC₅₀ values of 12.61 nM and 15.80 nM for JAK2 and JAK3, respectively. TK4g can be used in lymphoid-derived diseases and leukemia cancer research .

HY-18200A

Atopaxar hydrochloride E5555 hydrochloride; ER-172594-00 hydrochloride	Protease Activated Receptor (PAR) JAK Apoptosis	Cardiovascular Disease Cancer
Atopaxar hydrochloride (E5555 hydrochloride) is the hydrochloride salt form of Atopaxar (HY-18200). Atopaxar hydrochloride is an orally active, selective and reversible antagonist for thrombin receptor protease-activated receptor-1 (PAR-1). Atopaxar hydrochloride is the inhibitor for Janus kinase 1 (JAK1) and JAK2, which inhibits the JAK-STAT with EC₅₀ of 5.90 μM in A549. Atopaxar hydrochloride inhibits the cell viability of A549 (IC₅₀=7.02 μM), arrests the cell cycle at G1 phase and induces apoptosis. Atopaxar hydrochloride exhibits antiplatelet and antitumor activities. Atopaxar hydrochloride can be used for the research of atherothrombotic disease .

HY-183670

JAK2-IN-21	JAK STAT Apoptosis	Infection Cancer
JAK2-IN-21 is a Janus kinase 2 (JAK2) inhibitor with an IC₅₀ of 12.25 nM. JAK2-IN-21 inhibits the JAK2/STAT3/STAT5 tumor-promoting signaling pathway and reduces JAK2 protein expression. JAK2-IN-21 exhibits selective cytotoxicity against HPV-positive cancer cells and induces cancer cell apoptosis. JAK2-IN-21 can be used in the research of HPV-positive cervical cancer .

HY-E70835

JAK2(JH1/JH2) Recombinant Human Active Protein Kinase	JAK	Cancer
Janus kinase 2 (JAK2) initiates signaling from several cytokine receptors and is required for biological responses such as erythropoiesis. JAK2 contains the kinase (JH1) and pseudokinase domains (JH2). JAK2(JH1/JH2) Recombinant Human Active Protein Kinase is a recombinant JAK2(JH1/JH2) protein that can be used to study JAK2(JH1/JH2)-related functions .

Cat. No.	Product Name

HY-L008

JAK/STAT Compound Library	704 compounds
The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID). MCE provides 704 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.

JAK/STAT Compound Library

704 compounds

The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID).

MCE provides 704 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2521

Tetramethylcurcumin FLLL31	other families Classification of Application Fields Phenols Plants Inflammation/Immunology Disease Research Fields Source Classification	STAT Apoptosis
Tetramethylcurcumin (FLLL31), derived from curcumin, specifically suppresses the phosphorylation of STAT3 by binding selectively to Janus kinase 2 and the STAT3 Src homology-2 domain. Tetramethylcurcumin exhibits anti-inflammatory and anti-cancer effects .

Recombinant Proteins Recommended:

Janus kinase

Species:	Human (15)
Tag:	His (11) Strep (1) Tag Free (1) Avi (4) GST (7)
Source:	sf9 insect cells (1) P. pastoris (2) Sf9 insect cells (10) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P7989

	Janus kinase 2/JAK2 Protein, Human (His) 2 Publications Verification JAK2, Janus kinase 2	Human	E. coli
	Janus kinase 2/JAK2 Protein, Human (His) is a recombinant human JAK2 expressed in E. coli with a His tag at the N-terminus. JAK2 is a non-receptor tyrosine kinase.

HY-P705808

	Janus kinase 2/JAK2 Protein, Human (Inactive, Biotinylated, V617F, sf9, Avi) JAK2, Janus kinase 2	Human	sf9 insect cells

HY-P704597

	Janus kinase 2/JAK2 Protein, Human (Biotinylated, sf9, Avi) JAK2; Janus kinase 2; tyrosine-protein kinase JAK2; JTK10; JAK-2; Janus kinase 2 (a protein tyrosine kinase); THCYT3	Human	Sf9 insect cells
	The Janus kinase 2 (JAK2) protein is a critical non-receptor tyrosine kinase that drives important cellular processes affecting growth, development, differentiation, and histone modifications. JAK2 plays a role in innate and adaptive immunity, interacting with receptors such as growth hormone, erythropoietin, and interleukins. Janus kinase 2/JAK2 Protein, Human (Biotinylated, sf9) is the recombinant human-derived Janus kinase 2/JAK2 protein, expressed by Sf9 insect cells, with tag free.

HY-P706033

	Janus kinase 2/JAK2 Protein, Human (Inactive, sf9, His-GST) Tyrosine-protein kinase JAK2; Janus kinase 2; JAK-2	Human	Sf9 insect cells

HY-P706061

	Janus kinase 2/JAK2 Protein, Human (Active, sf9, His-GST) Tyrosine-protein kinase JAK2; Janus kinase 2; JAK-2	Human	Sf9 insect cells

HY-P706060

	Janus kinase 2/JAK2 Protein, Human (Inactive, V617F, sf9, His-GST) Tyrosine-protein kinase JAK2; Janus kinase 2; JAK-2	Human	Sf9 insect cells

HY-P706062

	Janus kinase 2/JAK2 Protein, Human (Active, JH2-JH1, sf9, His-GST) Tyrosine-protein kinase JAK2; Janus kinase 2; JAK-2	Human	Sf9 insect cells

HY-P702721

	JAK3 Protein, Human (Active, sf9, GST) JAK3; Janus kinase 3; tyrosine-protein kinase JAK3; JAK 3; JAK3_HUMAN; JAKL; L JAK; leukocyte Janus kinase; LJAK; tyrosine protein kinase JAK3; Janus kinase 3 (a protein tyrosine kinase, leukocyte); JAK-3; L-JAK	Human	Sf9 insect cells
	JAK3 Protein, Human (sf9, GST) is the recombinant human-derived JAK3, expressed by Sf9 insect cells , with GST labeled tag. ,

HY-P705710

	JAK3 Protein, Human (Biotinylated, Inactive, sf9, Avi-His) Tyrosine-protein kinase JAK3; EC:2.7.10.2; Janus kinase 3 (JAK-3); Leukocyte janus kinase (L-JAK); JAK3	Human	Sf9 insect cells

HY-P705709

	Janus kinase 2/JAK2 Protein, Human (Inactive, V617F, sf9, StrepII, His, Avi) Tyrosine-protein kinase JAK2; EC:2.7.10.2; Janus kinase 2 (JAK-2); JAK2	Human	Sf9 insect cells

HY-P701102

	Janus kinase 2/JAK2 Protein, Human (381a.a, His) 1 Publications Verification JAK 2; JAK-2; JAK2; JAK2_HUMAN; Janus Activating Kinase 2; Janus kinase 2 (a protein tyrosine kinase); Janus kinase 2; JTK 10; JTK10; kinase Jak2; OTTHUMP00000043260; THCYT3; Tyrosine protein kinase JAK2; Tyrosine-protein kinase JAK2	Human	E. coli
	Janus kinase 2/JAK2 Protein, Human is a recombinant human JAK2 expressed in E. coli with a His tag at the N-terminus. JAK2 is a non-receptor tyrosine kinase.

HY-P700583

	JAK1 Protein, Human (P. pastoris, His) 4 Publications Verification JAK1; JAK1A; JAK1B; Tyrosine-protein kinase JAK1; Janus kinase 1; JAK-1	Human	P. pastoris
	JAK1 protein is a non-receptor tyrosine kinase that plays a crucial role in IFN-α/β/γ signaling and serves as a kinase partner for IL-2 and IL-10 receptors. It cooperates with the type I interferon receptor IFNAR2 to phosphorylate and activate IFNAR2 upon interferon binding to IFNAR1-IFNAR2. JAK1 Protein, Human (P. pastoris, His) is the recombinant human-derived JAK1 protein, expressed by P. pastoris , with N-6*His labeled tag.

HY-P706063

	JAK1 Protein, Human (Active, sf9, His-GST) Tyrosine-protein kinase JAK1; Janus kinase 1; JAK-1; JAK1A; JAK1B	Human	Sf9 insect cells

HY-P705571

	JAK1 Protein, Human (Active, sf9, GST) Tyrosine-protein kinase JAK1; Janus kinase 1 (JAK-1); JAK1A, JAK1B; EC:2.7.10.2	Human	Sf9 insect cells

HY-P71785

	SOCS1 Protein, Human (P.pastoris, His) CISH 1; CISH1; Cytokine inducible SH2 protein 1; JAB; JAK binding protein; JAK-binding protein; Janus kinase binding protein ; SOCS 1; TEC interacting protein 3; Tec-interacting protein 3; TIP 3	Human	P. pastoris
	The SOCS1 protein is an important negative regulator that inhibits type I and type II interferon signaling as well as cytokines such as IL2, IL4, IL6, and LIF. It downregulates the signaling of the JAK/STAT pathway by inhibiting JAK proteins and IFNGR1. SOCS1 Protein, Human (P.pastoris, His) is the recombinant human-derived SOCS1 protein, expressed by P. pastoris , with N-His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-W727879

Upadacitinib-15N,d2

1 Publications Verification

Upadacitinib- ¹⁵N,d₂ (ABT-494- ¹⁵N,d₂) is the deuterium-labeled Upadacitinib (HY-19569). Upadacitinib- ¹⁵N,d₂ (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib- ¹⁵N,d₂ (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib- ¹⁵N,d₂ (ABT-494) can be used for several autoimmune disorders research .

Host:	Mouse (3) Rabbit (8)
Reactivity:	Human (11) Rat (6) Mouse (6)
Application:	IHC-P (5) ICC/IF (8) IF-Tissue (1) IP (6) IHC-F (1) WB (10) FC (2) ELISA (2)
Isotype:	IgG (7) IgG2a (2) IgG/Kappa (1)
Conjugation:	Non-conjugated (11) Biotin (3)
Clonality:	Polyclonal (1) Monoclonal (8) Recombinant (4)
Modification:	Phosphorylated (1) Unmodified (8)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P85716

	JAK3 Antibody (YA5408) Tyrosine-protein kinase JAK3; Janus kinase 3; JAK-3; Leukocyte janus kinase; L-JAK;	IHC-P	Human, Mouse, Rat
	JAK3 Antibody (YA5408) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to JAK3.

HY-P82721

	JAK3 Antibody (YA2466) JAK3; Tyrosine-protein kinase JAK3; Janus kinase 3; JAK-3; Leukocyte janus kinase; L-JAK	WB, ICC/IF	Human
	JAK3 Antibody (YA2466) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to JAK3.

HY-P85234

	JAK3 Antibody (YA4926) JAK3; Tyrosine-protein kinase JAK3; Janus kinase 3; JAK-3; Leukocyte janus kinase; L-JAK	WB, IHC-P, IHC-F, ICC/IF, IF-Tissue	Human
	JAK3 Antibody (YA4926) is a Rabbit-derived and non-conjugated monoclonal antibody, targeting to JAK3.

HY-P86474

	JAK3 Antibody (YA6166) JAK3; Tyrosine-protein kinase JAK3; Janus kinase 3; JAK-3; Leukocyte janus kinase; L-JAK	WB, ICC/IF, IP, ELISA	Human
	JAK3 Antibody (YA6166) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to JAK3.

HY-P80727

	JAK2 Antibody (YA330) 1 Publications Verification JAK2; Tyrosine-protein kinase JAK2; Janus kinase 2; JAK-2	WB	Human, Mouse
	JAK2 Antibody (YA330) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to JAK2.

HY-P86385

	JAK2 Antibody (YA6077) Tyrosine-protein kinase JAK2 (EC 2.7.10.2) (Janus kinase 2) (JAK-2)	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	JAK2 Antibody (YA6077) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to JAK2.

HY-P80829

	Phospho-JAK2 (Tyr1007/1008) Antibody JAK2; Tyrosine-protein kinase JAK2; Janus kinase 2; JAK-2	WB, IHC-P, ICC/IF, IP, FC	Human, Mouse, Rat
	Phospho-JAK2 (Tyr1007/1008) Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Phospho-JAK2 (Tyr1007/1008).

HY-P80727A

	JAK2 Antibody (YA330)(PBS only) JAK2; Tyrosine-protein kinase JAK2; Janus kinase 2; JAK-2	WB	Human, Mouse
	JAK2 Antibody (YA330) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to JAK2.

HY-P80829A

	Phospho-JAK2 (Tyr1007/1008) Antibody (YA6449) 1 Publications Verification JAK2; Tyrosine-protein kinase JAK2; Janus kinase 2; JAK-2	WB, IHC-P, ICC/IF, IP, FC	Human, Mouse, Rat
	Phospho-JAK2 (Tyr1007/1008) Antibody (YA6449) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-JAK2 (Tyr1007/1008).

HY-P80726

	JAK1 Antibody (YA722) JAK1; JAK1A; JAK1B; Tyrosine-protein kinase JAK1; Janus kinase 1; JAK-1	WB, ICC/IF, IP	Human, Rat
	JAK1 Antibody (YA722) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to JAK1.

HY-P80726A

	JAK1 Antibody (YA722)(PBS only) JAK1; JAK1A; JAK1B; Tyrosine-protein kinase JAK1; Janus kinase 1; JAK-1	WB, ICC/IF, IP	Human, Rat
	JAK1 Antibody (YA722) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to JAK1.